ARQ-151 not checked

Arcutis Biotherapeutics, Inc. · Roflumilast Cream 0.15% · Roflumilast Foam 0.3%

FollowEvery change as it happens, and a Monday email
Stage
in the US
Next date
Phase 4 trial completes
Trials
2 active
24 in total · 1 in the EU
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“Roflumilast cream 0.3% administered topically once daily to affected areas during the 4-week double-blind treatment period. Participants may continue treatment with roflumilast cream 0.3% during the 48-week open-label extension.”In the company’s words, NCT07916480 on ClinicalTrials.gov
Tested for
Atopic Dermatitis (2 trials), ITCH, Atopic Dermatitis (AD), Atopic Dermatitis (Eczema)
Main trialPhase 4
“This study is being done to obtain descriptive classifications of pruritus using a patient directed survey system and assess change in pruritus over time in patients with Atopic Dermatitis over 4 weeks with use of topical Roflumilast cream 0.15% QD.”In the company’s words, NCT07560618 on ClinicalTrials.gov
Other names
Roflumilast Cream 0.15% · Topical roflumilast · Roflumilast Foam 0.3% · Roflumilast Cream · Roflumilast Cream 0.05% · Roflumilast 0.3% cream · ARQ-154 · Roflumilast Foam · Roflumilast · ARQ-154 0.3% · Roflumilast Cream 0.3%

Other drugs for Atopic Dermatitis

All 90 drugs for Atopic Dermatitis

Coming up2

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials24

TrialPhaseCompletesWhat it tests
Phase 4Recruiting Aug 2027 Obtaining Descriptive Classifications of Pruritus and Assessing Change in Pruritus Over Time in Atopic Dermatitis Patients Using Topical Roflumilast Cream.
Phase 3Recruiting 27 Apr 2028 Roflumilast Cream 0.3% for Moderate to Severe Atopic Dermatitis
Phase 3Completed 16 Nov 2020 Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis
Phase 3Completed 23 Nov 2020 Twin Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis
Phase 3Completed 6 Apr 2022 Trial of PDE4 Inhibition With Roflumilast (ARQ-154) Foam 0.3% for the Management of Seborrheic Dermatitis (STRATUM)
Phase 3Completed 3 Jun 2022 Topical Roflumilast to Treat Scalp and Body Psoriasis (ARRECTOR)
Phase 3Completed 30 Aug 2022 Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis
Phase 3Completed 29 Sep 2022 Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (INTEGUMENT-II)
Phase 3Completed 1 Jun 2023 Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (Integument-PED)
Phase 3Completed 22 Jan 2024 Open-Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis
Phase 3Completed 28 May 2024 Open Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis
Phase 2Completed 29 May 2019 The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis
Phase 2Completed 4 Nov 2019 Safety and Efficacy of ARQ-151 Cream in Adolescents and Adults With Atopic Dermatitis
Phase 2Completed 18 Aug 2020 Safety and Efficacy of ARQ-154 Foam in Subjects With Seborrheic Dermatitis
Phase 2Completed 23 Sep 2020 Safety and Efficacy of ARQ-154 Foam in Adolescent and Adult Subjects With Scalp and Body Psoriasis
Phase 2Completed 12 Jan 2022 Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-215)
Phase 2Completed 11 May 2022 Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-216)
Phase 2Completed 19 Nov 2022 Long-Term Safety of ARQ-154 Foam in Subjects With Seborrheic Dermatitis
Phase 2Completed 4 Dec 2025 Safety Study of Roflumilast Cream 0.05% in Infants Aged 3 Months to Less Than 2 Years With Atopic Dermatitis
Phase 1/2Completed 2 May 2018 Safety, Pharmacokinetics and Efficacy of ARQ-151 Cream in Adults With Mild to Moderate Chronic Plaque Psoriasis
Phase 1Completed 25 Mar 2021 Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Adolescents and Adults With Chronic Plaque Psoriasis
Phase 1Completed 2 May 2023 Pharmacokinetics (PK), Safety, Efficacy and Maximal Use PK of ARQ-151 in Adolescents/Children With Mild/Moderate Eczema
Phase 1Completed 30 Apr 2026 Maximal Usage Pharmacokinetics and Safety Study of ARQ-154 Foam 0.3% in Pediatric Participants With Scalp and Body Psoriasis
Phase 2Ended not given Treatment of Chronic Hand Eczema with Oral Roflumilast (HERO) – a randomized controlled trial
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow ARQ-151

Following is part of Solo: you see every change to ARQ-151 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in